Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Authors:
- Rikke JensenRJRikke Jensen
- R. Philip KinkelRKR. Philip Kinkel
Open Access
- 1 February 2011
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (2) , 186-191
Abstract
Natalizumab, a humanized monoclonal antibody against α4 integrin, has been shown to significantly reduce the rate of clinical relapse, the development of T2 and gadolinium-enhancing magnetic resonance imaging (MRI) lesions, and the progression of disability in patients with relapsing forms of multiple sclerosis (MS).1,2 There have been more than 50 cases of progressive multifocal leukoencephalopathy (PML) in patients with MS receiving natalizumab, all developing after at least 1 year of therapy. Evidence suggests that the risk of developing PML is higher with prolonged periods of immunosupression.3Keywords
This publication has 10 references indexed in Scilit:
- Severe relapses after the first infusion of natalizumab in active relapsing—remitting multiple sclerosisMultiple Sclerosis Journal, 2009
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionNeurology, 2009
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyNeurology, 2009
- POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTSNeurology, 2008
- Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?Annals of Neurology, 2006
- Immune surveillance in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Randomized multicenter trial of natalizumab in acute MS relapsesNeurology, 2004
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003
- Inflammatory Reactions in HIV-1–Infected Persons after Initiation of Highly Active Antiretroviral TherapyAnnals of Internal Medicine, 2000